The Clorox Company's (NYSE:CLX) intrinsic value looks set to rise substantially above its share price, signaling a strong position in the market. With
9,641 CLX shares bought by Miracle Mile Advisors LLC, and a strong performance against competitors, Clorox continues to solidify its stand in the market. The announcement of its
Q2 2025 earnings release, along with future projections, have piqued investor interest. However, price targets for Clorox have been lowered to $130.00 at Barclays. Despite this, the company's institutional ownership stands at an impressive 81%, with substantial stakes held by the
Czech National Bank and
Assenagon Asset Management S.A. Furthermore, Clorox's new operating model aims for annual savings of $100M, partnering with M2030 to advance supply chain climate action. Interestingly, Clorox's quarterly dividend remains consistent at $1.22 per share, despite its share price performance. Its recent investments aid in strengthening the global supply chain ethics with enhanced human rights partnerships.
Clorox's FY24 integrated annual report, along with its incoming revenue from the sale of Better Health VMS Business and numerous new board member announcements further increases the attractiveness of the stock.
Clorox Company CLX News Analytics from Wed, 28 Feb 2024 08:00:00 GMT to Sat, 18 Jan 2025 16:12:14 GMT -
Rating 7
- Innovation 8
- Information 8
- Rumor 0
